Home arrow ABOUT US
ABOUT US
image
SunBio The PEGylation Expert
Welcome to SunBio
SunBio is a biotechnology company specializing in the development of biosimilars, biopharmaceuticals, and medical devices, with a strong foundation in proprietary PEGylation technologies.

Our biosimilar product, PEG-filgrastim, has been successfully marketed in the EU (as Pelgraz) and Canada (as Lapelga) since 2018, Mexico and Australia since 2022, and in India since 2008. In the medical device sector, MucoPEG, designed for the treatment of xerostomia, received FDA clearance for marketing in the United States in 2019.

Building on these achievements, SunBio continues to advance an innovative pipeline that includes a blood substitute, a novel therapy for gout, and a next-generation lipid nanoparticle (LNP) delivery platform for mRNA vaccines and oncology applications. Our ongoing research focuses on developing new approaches to PEGylation that minimize its limitations while amplifying its proven benefits.

In addition, SunBio provides a wide range of activated PEG derivatives, essential components in advanced PEGylation applications. These are manufactured in our EMA-approved GMP facility, ensuring the highest standards of quality and reliability.